Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms of resistance and developmental strategies without systematic review methodology or primary data.
PubMed 38739466 · doi:10.1080/1744666X.2024.2349738
What was done
This narrative review synthesized current evidence on the mechanisms underlying primary resistance and post-response relapse following chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, as well as emerging technological and clinical strategies designed to overcome treatment failure.
What was found
The authors report that only approximately 50% of patients with relapsed B-cell hematologic malignancies achieve complete, sustained responses. Primary resistance is attributed to manufacturing failures, suboptimal baseline fitness of autologous T-cells, and intrinsic tumor or microenvironmental factors. Relapse is categorized into antigen-positive failure (driven by CAR T-cell exhaustion or limited persistence) and antigen-negative failure (driven by target antigen modulation). No additional quantitative metrics were provided in the abstract.
Why it matters
Understanding the distinct biological pathways leading to CAR-T failure is critical for designing next-generation cell constructs, optimized pre-conditioning regimens, and rational combination immunotherapies to achieve durable remissions.
Limits
The paper is a non-systematic narrative review providing broad expert commentary without formal meta-analytic pooling, systematic search criteria, or primary clinical trial data.
Cited by
- context CAR-T cell therapies involve engineering T cells with specialized receptors to target tumors, but often fail in patients due to the immune system shutting down or cells failing to eliminate the tumor.